RSS-Feed abonnieren
DOI: 10.1055/s-0038-1637766
Capacities and Competences for Drug Evaluation in European Neonatal Intensive Care Units: A Survey and Key Issues for Improvement
Funding The research leading to these results has received funding from the European Union Seventh Framework Program FP7 (2007–2013) under grant agreement no. 261060 (Global Research in Pediatrics Network, GRiP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Publikationsverlauf
Publikationsdatum:
25. April 2018 (online)
![](https://www.thieme-connect.de/media/ajp/201806/lookinside/thumbnails/10-1055-s-0038-1637766_18iccn15-1.jpg)
Abstract
Background Multicenter neonatal clinical trials aim to provide evidence-based drug evaluation, but recruiting neonates requires collaboration, standard procedures, and trained neonatologists.
Methods A questionnaire based on a previous Delphi study was sent to European neonatal intensive care units (NICUs) to collect their research experience and identify areas for improvement.
Results Of 247 NICUs,79 (32%) responded: 69 were level III units and 10 were level II units. In level III centers, 62% had medical staff dedicated to research and 65% conducted regular in-house audits. Similarities were observed in the median number of trials per year (level II: 2; level III: 5), Good Clinical Practice training (level II: 78%; level III: 66%), and standard operating procedures (level II: 63%; level III: 71%). Most NICUs had access to scientific advice for trial design, conduct, data management, and regulatory aspects. Involvement of patient advocacy groups was more common in level II units (level II: 75%; level III: 59%). A “quality” score of 34 “quality” research items was calculated for all centers (mean: 23.2 ± 6.2; range: 6–34).
Conclusion Research experience and processes vary across Europe. Harmonizing research practices and setting standards will allow building a European neonatal network for effective, safe, and quality neonatal drug development.
Keywords
neonate - intensive care unit - clinical research - good clinical practices - training - proceduresAuthors' Contributions
V. E., V. N., S. L., and E. J. A. conceived and designed the experiments. V. E., V. N., and S. L. performed the experiments. V. E., V. N., P. H., and E. J. A. analyzed the data. V. E., V. N., P. H., B. A., S. L., and E. J. A. contributed reagents/materials/analysis tools. V. E., V. N., B. A., S. L., and E. J. A. wrote the article.
Note
The datasets generated and/or analyzed during this study are available from the corresponding author on reasonable request.
-
References
- 1 Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005; 164 (09) 552-558
- 2 Choonara I. Rational prescribing is important in all settings. Arch Dis Child 2013; 98 (09) 720
- 3 Leroux S, Zhao W, Bétrémieux P, Pladys P, Saliba E, Jacqz-Aigrain E. ; French Society of Neonatology. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. Arch Dis Child 2015; 100 (04) 394-398
- 4 Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006. Available at: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf . Accessed February 13, 2017
- 5 Choonara I. Regulation of drugs for children in Europe. BMJ 2007; 335 (7632): 1221-1222
- 6 Guideline on the investigation of medicinal products in the term and preterm neonate - WC500003754.pdf. Available at: http://www.ema.europa.eu/docs . Accessed April 26, 2017
- 7 Legrand F, Boulkedid R, Elie V. , et al. A Delphi process to optimize quality and performance of drug evaluation in neonates. PLoS One 2014; 9 (09) e104976
- 8 Pansieri C, Bonati M, Choonara I, Jacqz-Aigrain E. Neonatal drug trials: impact of EU and US paediatric regulations. Arch Dis Child Fetal Neonatal Ed 2014; 99 (05) F438
- 9 Wimmer S, Rascher W, McCarthy S, Neubert A. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans. Paediatr Drugs 2014; 16 (05) 397-406
- 10 Mentzer D. Progress review of the European Paediatric Regulatory Framework after six years of implementation. Int J Pharm 2014; 469 (02) 240-243
- 11 Turner MA, Catapano M, Hirschfeld S, Giaquinto C. ; Global Research in Paediatrics. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014; 73: 2-13
- 12 Ruggieri L, Giannuzzi V, Baiardi P. , et al; GRiP Consortium. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr 2015; 174 (04) 481-491
- 13 Ligi I, Boubred F, Grandvuillemin I, Simeoni U. Clinical research in newborn infants: difficulties and specificity. Eur J Clin Pharmacol 2011; 67 (Suppl. 01) 29-32
- 14 Joseph PD, Craig JC, Tong A, Caldwell PHY. Researchers', regulators', and sponsors' views on pediatric clinical trials: a multinational study. Pediatrics 2016; 138 (04) 138
- 15 State of Paediatric Medicines in the EU 10 years of the EU Paediatric Regulation-Report from the Commission to the European Parliament and the Council. COM (2017) 626, Available at: https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs 2017_childrensmedicines_report_en.pdf . Accessed March 5, 2018
- 16 Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One 2011; 6 (06) e20476
- 17 Stark AR. ; American Academy of Pediatrics Committee on Fetus and Newborn. Levels of neonatal care. Pediatrics 2004; 114 (05) 1341-1347
- 18 ICH topic E11 Clinical investigation of medicinal products in the paediatric population. 2001 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf . Accessed March 5, 2018
- 19 Paramasivan S, Strong S, Wilson C, Campbell B, Blazeby JM, Donovan JL. A simple technique to identify key recruitment issues in randomised controlled trials: Q-QAT - Quanti-Qualitative Appointment Timing. Trials 2015; 16: 88
- 20 Mudd LM, Pham X, Nechuta S, Elliott MR, Lepkowski JM, Paneth N. ; Michigan Alliance for the National Children's Study. Prenatal care and delivery room staff attitudes toward research and the National Children's Study. Matern Child Health J 2008; 12 (06) 684-691
- 21 Lake ET, Staiger D, Horbar J. , et al. Association between hospital recognition for nursing excellence and outcomes of very low-birth-weight infants. JAMA 2012; 307 (16) 1709-1716
- 22 Smith OM, Dale C, Mehta S, Pinto R, Rose L. Nurse research experiences and attitudes toward the conduct of intensive care research: a questionnaire study. Crit Care Med 2016; 44 (01) 153-161
- 23 Cleveland LM. Parenting in the neonatal intensive care unit. J Obstet Gynecol Neonatal Nurs 2008; 37 (06) 666-691
- 24 Mason SA, Allmark PJ. Obtaining informed consent to neonatal randomised controlled trials: interviews with parents and clinicians in the Euricon study. Lancet 2000; 356 (9247): 2045-2051
- 25 Hoehn KS, Wernovsky G, Rychik J. , et al. What factors are important to parents making decisions about neonatal research? Arch Dis Child Fetal Neonatal Ed 2005; 90 (03) F267-F269
- 26 Spilsbury K, Petherick E, Cullum N, Nelson A, Nixon J, Mason S. The role and potential contribution of clinical research nurses to clinical trials. J Clin Nurs 2008; 17 (04) 549-557